Nizatidine 150mg/5ml oral solution
Requires a prescription from a doctor or prescriber
A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Nizatidine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Nizatidine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
300 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 10 · Randomised trials: 2 · 1986–2025
Showing the 50 most relevant studies, sorted by most relevant.
Satbir Singh, Dr. Gaikwad Dushyant Dadabhau, Kehar Singh
European Chemical Bulletin, 2022
S ORENSTEIN, David A. Gremse, Carmela Pantaleon, et al.
Clinical Therapeutics, 2005
- Capsules
- Chemistry, Pharmaceutical
- Drug Tolerance
Michelle C. Carlson, JoAnn T. Tschanz, Maria C. Norton, et al.
Alzheimer Disease & Associated Disorders, 2002
- Alzheimer Disease
- Histamine H2 Antagonists
- Neuropsychological Tests
Chuka Nwokolo, Jeff Smith, C. J. Gavey, et al.
Alimentary Pharmacology & Therapeutics, 1990
- Cimetidine
- Drug Tolerance
- Gastric Acid
Shivani Dhorajiya, Janki Goswami, Bhumika Dudhatra, et al.
2024
Nishita Mehta
Journal of Population Therapeutics & Clinical Pharmacology, 2025
Steven Wrighton, Barbara J. Ring
Pharmaceutical Research, 1994
- Cytochrome P-450 Enzyme Inhibitors
- Chromatography, High Pressure Liquid
- Cimetidine
Douglas M. Morton
Scandinavian Journal of Gastroenterology, 1987
- Carcinogens
- Histamine H2 Antagonists
- Mutagens
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
89 found
Half-life
1-2 hours
Mechanism
Nizatidine competes with histamine for binding at the H2-receptors on the gastri…
Food interactions
3 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
70%
Half-life
1-2 hours
Protein binding
35%
Volume of distribution
0.8 to 1.5 L/kg
Metabolism
7%
Clearance
40-60 L/h
* 7 – 14 L/h [functionally anephric patients]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 499 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
* 7 – 14 L/h [functionally anephric patients]
Proteins and enzymes this drug interacts with in the body
The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC A02BA04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Nizatidine
Additional database identifiers
Drugs Product Database (DPD)
1305
ChemSpider
4356
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5183
GenAtlas
HRH2
GeneCards
HRH2
GenBank Gene Database
M64799
GenBank Protein Database
184088
Guide to Pharmacology
263
UniProt Accession
HRH2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q1188290), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.